Skip to main content
SpringerLink
Log in

Special Situations in APL

  • Chapter
  • First Online:
Acute Promyelocytic Leukemia

  • 624 Accesses

Abstract

The introduction of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) as the mainstay therapy of acute promyelocytic leukemia (APL) has drastically changed the outcome of this hematologic malignancy into one of the first to receive a targeted treatment. Using frontline treatment strategies including these agents in combination with standard cytotoxic drugs has provided outstanding therapeutic results in most patients. In spite of the achievement of brilliant results in the majority of patients, some special situations still require the implementation of changes from the conventional therapeutic approach. In this chapter, we will review and discuss the management of APL in older and frail patients, children and pregnant women, as well as those with therapy-related leukemia, extramedullary relapse, and the extremely rare situation of the genetic variants.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Sanz MA, Vellenga E, Rayon C, Diaz-Mediavilla J, Rivas C, Amutio E, et al. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood. 2004;104(12):3490–3.

    Article  CAS  PubMed  Google Scholar 

  2. Mandelli F, Latagliata R, Avvisati G, Fazi P, Rodeghiero F, Leoni F, et al. Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. Leukemia. 2003;17(6):1085–90.

    Article  CAS  PubMed  Google Scholar 

  3. Lengfelder E, Hofmann WK, Nolte F. Management of elderly patients with acute promyelocytic leukemia: progress and problems. Ann Hematol. 2013;92(9):1181–8.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Ades L, Chevret S, De Botton S, Thomas X, Dombret H, Beve B, et al. Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience. Leukemia. 2005;19(2):230–3.

    Article  CAS  PubMed  Google Scholar 

  5. Latagliata R, Breccia M, Fazi P, Vignetti M, Di Raimondo F, Sborgia M, et al. GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukemia. Long-term results and prognostic factors. Br J Haematol. 2011;154(5):564–8.

    Article  CAS  PubMed  Google Scholar 

  6. Zhang Y, Zhang Z, Li J, Li L, Han X, Han L, et al. Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia. Cancer. 2013;119(1):115–25.

    Article  CAS  PubMed  Google Scholar 

  7. Lo Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111–21.

    Article  CAS  PubMed  Google Scholar 

  8. Lo Coco F, Cimino G, Breccia M, Noguera NI, Diverio D, Finolezzi E, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood. 2004;104(7):1995–9.

    Article  CAS  PubMed  Google Scholar 

  9. Breccia M, Cimino G, Diverio D, Gentilini F, Mandelli F, Lo Coco F. Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia. Haematologica. 2007;92(9):1273–4.

    Article  CAS  PubMed  Google Scholar 

  10. Testi AM, D’Angiò M, Locatelli F, Pession A, Lo Coco F. Acute promyelocytic leukemia (APL): comparison between children and adults. Mediterr J Hematol Infect Dis. 2014;6(1):e2014032.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Mann G, Reinhardt D, Ritter J, et al. Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children. Ann Hematol. 2001;80(7):417–22.

    Article  CAS  PubMed  Google Scholar 

  12. de Botton S, Coiteux V, Chevret S, et al. Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. J Clin Oncol. 2004;22(8):1404–12.

    Article  PubMed  Google Scholar 

  13. Testi AM, Biondi A, Lo Coco F, et al. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood. 2005;106(2):447–53.

    Article  CAS  PubMed  Google Scholar 

  14. Ortega JJ, Madero L, Martin G, et al. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. J Clin Oncol. 2005;23(30):7632–40.

    Article  CAS  PubMed  Google Scholar 

  15. Bally C, Fadlallah J, Leverger G, et al. Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group. J Clin Oncol. 2012;30(14):1641–6.

    Article  CAS  PubMed  Google Scholar 

  16. Abla O, Ribeiro RC. How I treat children and adolescents with acute promyelocytic leukemia. Br J Haematol. 2014;164(1):24–38.

    Article  CAS  PubMed  Google Scholar 

  17. Castaigne S, Lefebvre P, Chomienne C, et al. Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute promyelocytic leukemia. Blood. 1993;82(12):3560–3.

    CAS  PubMed  Google Scholar 

  18. Wang SJ, Silberstein SD, Patterson S, Young WB. Idiopathic intracranial hypertension without papilledema: a case-control study in a headache center. Neurology. 1998;51(1):245–9.

    Article  CAS  PubMed  Google Scholar 

  19. Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C971. Blood 2010; 116(19): 3751–3757.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Takahashi H, Watanabe T, Kinoshita A, et al. High event-free survival rate with minimum-dose-anthracycline treatment in childhood acute promyelocytic leukaemia: a nationwide prospective study by the Japanese Paediatric Leukaemia/Lymphoma Study Group. Br J Haematol. 2016;174(3):437–43.

    Article  CAS  PubMed  Google Scholar 

  21. Fox E, Razzouk BI, Widemann BC, et al. Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood. 2008;111(2):566–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. George B, Mathews V, Poonkuzhali B, Shaji RV, Srivastava A, Chandy M. Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience. Leukemia. 2004;18(10):1587–90.

    Article  CAS  PubMed  Google Scholar 

  23. Milligan DW, Grimwade D, Cullis JO, et al. Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol. 2006;135(4):450–74.

    Article  CAS  PubMed  Google Scholar 

  24. Verma V, Giri S, Manandhar S, Pathak R, Bhatt VR. Acute promyelocytic leukemia during pregnancy: a systematic analysis of outcome. Leuk Lymphoma. 2016;57(3):616–22.

    CAS  PubMed  Google Scholar 

  25. Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med. 1985;313(14):837–41.

    Article  CAS  PubMed  Google Scholar 

  26. Sanz MA, Montesinos P, Casale MF, et al. Maternal and fetal outcomes in pregnant women with acute promyelocytic leukemia. Ann Hematol. 2015;94(8):1357–61.

    Article  CAS  PubMed  Google Scholar 

  27. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol. 2004;5(5):283–91.

    Article  CAS  PubMed  Google Scholar 

  28. Culligan DJ, Merriman L, Kell J, et al. The management of acute promyelocytic leukemia presenting during pregnancy. Clin Leuk. 2007;1:183–91.

    Article  CAS  Google Scholar 

  29. U.S. Environmental Protection Agency. Arsenic compounds. http://www.epa.gov. Accessed 8 Jan 2008.

  30. Breccia M, Molica M, Efficace F, et al. Pregnancy in acute promyelocytic leukemia after frontline therapy with arsenic trioxide and all-trans retinoic acid. Br J Haematol. 2014;167(3):428–30.

    Article  CAS  PubMed  Google Scholar 

  31. Slattery MM, Morrison JJ. Preterm delivery. Lancet. 2002;360(9344):1489–97.

    Article  PubMed  Google Scholar 

  32. Royal College of Obstetricians and Gynecologists. Antenatal corticosteroids to reduce respiratory distress syndrome. Guideline No. 7. http://www.rcog.org.uk/resources/Public/pdf/Antenatal_corticosteroids_No7.pdf. Accessed 1 Apr 2007.

  33. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1999;94(4):1192–200.

    CAS  PubMed  Google Scholar 

  34. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337(15):1021–8.

    Article  CAS  PubMed  Google Scholar 

  35. Pulsoni A, Pagano L, Lo Coco F, et al. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. Blood. 2002;100(6):1972–6.

    Article  CAS  PubMed  Google Scholar 

  36. Beaumont M, Sanz M, Carli PM, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol. 2003;21(11):2123–37.

    Article  CAS  PubMed  Google Scholar 

  37. Mattson JC. Acute promyelocytic leukemia. From morphology to molecular lesions. Clin Lab Med. 2000;20(1):83–103, ix.

    CAS  PubMed  Google Scholar 

  38. Pollicardo N, O’Brien S, Estey EH, et al. Secondary acute promyelocytic leukemia. Characteristics and prognosis of 14 patients from a single institution. Leukemia. 1996;10(1):27–31.

    CAS  PubMed  Google Scholar 

  39. Mistry AR, Felix CA, Whitmarsh RJ, et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med. 2005;352(15):1529–38.

    Article  CAS  PubMed  Google Scholar 

  40. Andersen MK, Pedersen-Bjergaard J. Therapy-related MDS and AML in acute promyelocytic leukemia. Blood. 2002;100(5):1928–9; author reply 1929.

    Article  CAS  PubMed  Google Scholar 

  41. Pedersen-Bjergaard J. Insights into leukemogenesis from therapy-related leukemia. N Engl J Med. 2005;352(15):1591–4.

    Article  CAS  PubMed  Google Scholar 

  42. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003;102(1):43–52.

    Article  CAS  PubMed  Google Scholar 

  43. Pedersen-Bjergaard J, Philip P, Larsen SO, Jensen G, Byrsting K. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood. 1990;76(6):1083–91.

    CAS  PubMed  Google Scholar 

  44. Quesnel B, Kantarjian H, Bjergaard JP, et al. Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. J Clin Oncol. 1993;11(12):2370–9.

    Article  CAS  PubMed  Google Scholar 

  45. Ledda A, Caocci G, Spinicci G, Cocco E, Mamusa E, La Nasa G. Two new cases of acute promyelocytic leukemia following mitoxantrone treatment in patients with multiple sclerosis. Leukemia. 2006;20(12):2217–8.

    Article  CAS  PubMed  Google Scholar 

  46. Hasan SK, Mays AN, Ottone T, et al. Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood. 2008;112:3383–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Ottone T, Hasan SK, Montefusco E, et al. Identification of a potential “hotspot” DNA region in the RUNX1 gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation. Genes Chromosomes Cancer. 2009;48:213–21.

    Article  CAS  PubMed  Google Scholar 

  48. Ghalie RG, Mauch E, Edan G, et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler. 2002;8(5):441–5.

    Article  CAS  PubMed  Google Scholar 

  49. Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111–21.

    Article  CAS  PubMed  Google Scholar 

  50. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111(5):2505–15.

    Article  CAS  PubMed  Google Scholar 

  51. Adams J, Nassiri M. Acute promyelocytic leukemia: a review and discussion of variant translocations. Arch Pathol Lab Med. 2015;139(10):1308–13.

    Article  CAS  PubMed  Google Scholar 

  52. Koken MH, Daniel MT, Gianni M, et al. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. Oncogene. 1999;18(4):1113–8.

    Article  CAS  PubMed  Google Scholar 

  53. Specchia G, Lo Coco F, Vignetti M, et al. Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell’adulto. J Clin Oncol. 2001;19:4023–8.

    Article  CAS  PubMed  Google Scholar 

  54. De Botton S, Sanz M, Chevret S, et al. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. European APL group; PETHEMA Group. Leukemia. 2006;20:35–41.

    Article  PubMed  Google Scholar 

  55. Breccia M, Carmosino I, Diverio D, et al. Early detection of meningeal localization in acute promyelocytic leukemia patients with high presenting leukocyte count. Br J Haematol. 2003;120:266–70.

    Article  PubMed  Google Scholar 

  56. Sanz MA, Grimwade D, Tallmann MS, et al. Guidelines on the management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113:1875–91.

    Article  CAS  PubMed  Google Scholar 

  57. Breccia M, Petti MC, Testi AM, et al. Ear involvement in acute promyelocytic leukemia at relapse: a disease-associated sanctuary? Leukemia. 2002;16(6):1127–30.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy

    Massimo Breccia M.D., Ph.D.

  2. Department of Hematology, Hospital Universitari i Politècnic La Fe, Valencia, Spain

    Gloria Iacoboni Ph.D.

  3. Department of Medicine, Hospital Universitari i Politecnic La Fe, University of Valencia, Valencia, Spain

    Miguel A. Sanz M.D.

  4. Centro de Investigacion Biomedica en Red de Cancer, Instituto Carlos III, Madrid, Spain

    Miguel A. Sanz M.D.

Authors
  1. Massimo Breccia M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gloria Iacoboni Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Miguel A. Sanz M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Miguel A. Sanz M.D. .

Editor information

Editors and Affiliations

  1. Division of Hematology/Oncology, The Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada

    Oussama Abla

  2. Department of Hematology, University of Tor Vergata, Rome, Italy

    Francesco Lo Coco

  3. Department of Medicine, Hospital Universitari i Politecnic La Fe, University of Valencia, Valencia, Spain

    Miguel A. Sanz

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Cite this chapter

Breccia, M., Iacoboni, G., Sanz, M.A. (2018). Special Situations in APL. In: Abla, O., Lo Coco, F., Sanz, M. (eds) Acute Promyelocytic Leukemia . Springer, Cham. https://doi.org/10.1007/978-3-319-64257-4_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-64257-4_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-64256-7

  • Online ISBN: 978-3-319-64257-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation